Put the EUA for Baricitinib Plus Remdesivir in Perspective

The oral rheumatoid arthritis med baricitinib (Olumiant) is now authorized to treat COVID-19 in hospitalized patients.

It's a Janus kinase (JAK) inhibitor that blocks cytokines to decrease inflammation. Plus it may have antiviral effects.

Explain that evidence suggests ADDING baricitinib to remdesivir (Veklury) reduces recovery time by 1 day...compared to remdesivir alone. But it's too soon to say if the combo reduces mortality.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote